Last updated: February 14, 2026
Overview
NDC 00002-3115 refers to Remicade (infliximab), a monoclonal antibody used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. It is marketed by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary. As a biologic, its market dynamics and pricing are influenced by patent status, biosimilar development, manufacturing costs, and insurance coverage.
Market Size and Growth
The global infliximab market was valued at approximately $6.7 billion in 2020. It is projected to reach $9.2 billion by 2028, with a compound annual growth rate (CAGR) of roughly 4.2% [1].
Key factors include:
- Rising prevalence of autoimmune diseases.
- Increasing adoption of biologics as first-line treatment.
- Patent protections restricting biosimilar competition until recent years.
In the United States, infliximab sales accounted for nearly $4 billion in 2022, representing about 60% of the global market. Growth is driven by new indications and expanded patient access through biosimilars.
Patent and Regulatory Environment
- Janssen's patent exclusivity for Remicade expired in the US in 2018, allowing biosimilars to enter the market.
- Multiple biosimilars, including Remsima and Inflectra, are marketed in the US and abroad.
- Patent litigations and legal delays have affected biosimilar market penetration, sustaining higher prices for originator biologics.
Price Structure and Trends
List price:
- The average wholesale price (AWP) of Remicade in 2022 was approximately $1,200 per 100 mg vial.
- The typical regimen involves 3 mg/kg doses administered at weeks 0, 2, 6, then every 8 weeks.
- Annual treatment cost per patient ranges between $30,000 and $50,000, depending on dosage and infusion costs.
Pricing trends:
- Originator drugs like Remicade have maintained high prices due to patent protections and limited biosimilar competition until recent years.
- Biosimilar entry has resulted in price discounts of 15-30%, but fully comparable savings are delayed by prescribing inertia and insurance contracts.
- The average net price reductions for biosimilars in the US range between 10-25%, with prices sometimes below $800 per 100 mg vial as biosimilars gain wider adoption [2].
Competitive Landscape
| Product |
Type |
Launch Year |
Price Discount (vs. Originator) |
Market Share (2022) |
| Remicade (original) |
Biologic (infliximab) |
1998 |
Baseline |
Approx. 60% |
| Inflectra (biosimilar) |
Biosimilar |
2016 |
20-30% discount in list price |
25% |
| Renflexis (biosimilar) |
Biosimilar |
2017 |
Similar to Inflectra |
15% |
| Remsima (biosimilar) |
Biosimilar |
2017 |
Similar to Inflectra |
10% |
Price Projections (2023-2030)
- Short-term (2023-2025): Continued biosimilar market penetration will exert downward pressure on prices. Originator list prices are expected to decline 10-15% annually, driven by payer negotiations and biosimilar competition.
- Mid-term (2025-2028): Margin compression might stabilize as biosimilar adoption plateaus, with wholesale prices decreasing by 20-35% from 2022 levels.
- Long-term (2028-2030): Patent expirations for additional biologics and regulatory reforms could further reduce prices. However, the high cost of manufacturing biologics may limit steep price drops.
Regulatory and Policy Impact
- Increased biosimilar approval and interchangeability designations are expected to accelerate cost savings.
- Policies encouraging biosimilar uptake or incentivizing generic biologics could reduce the pharmaceutical spend on infliximab by up to 30% over the next five years.
Key Risks
- Slow biosimilar adoption due to prescriber and patient preferences.
- Legal disputes delaying biosimilar market entry or uptake.
- Variability in insurance coverage influencing patient out-of-pocket costs and access.
Key Takeaways
- The infliximab market is shifting from high-margin originators to biosimilars, reducing prices.
- In 2022, the wholesale price for Remicade was roughly $1,200 per 100 mg vial; net prices are often lower.
- Price declines are expected to continue at approximately 10-15% annually over the next two years, stabilizing around 20-35% from 2022 levels by 2028.
- Biosimilar competition is likely to accelerate cost reductions, though legal and market forces will influence actual price trajectories.
- The market size is expected to grow 4-5% annually, driven by increasing autoimmune disease prevalence and biosimilar uptake.
Frequently Asked Questions
1. How does biosimilar entry affect the price of infliximab?
Biosimilar approvals lead to price competition, typically resulting in a 15-30% list price reduction. Payers negotiate further discounts, lowering actual net prices.
2. What is the projected market size for infliximab biologics through 2030?
The market is forecasted to grow from approximately $6.7 billion in 2020 to over $9.2 billion by 2028, driven by increasing treatment rates.
3. How do legal patent disputes influence infliximab pricing?
Patent litigations can delay biosimilar entry, maintaining higher prices for originator drugs. Conversely, resolution often accelerates price declines.
4. To what extent can policy changes lower infliximab prices?
Policies promoting biosimilar substitution and insurance reforms could reduce costs by an additional 10-30% over the next five years.
5. What factors can cause actual prices to deviate from projections?
Market dynamics such as prescriber habits, insurance coverage policies, legal challenges, and manufacturing costs can cause deviations.
Sources
[1] Evaluate Pharma, "Global Biologic Market Outlook," 2023.
[2] IQVIA, "Biosimilar Markets and Pricing," 2022.
